Bronchiectasis - Institute for Respiratory Health

Bronchiectasis

Study Outline

The study aims to evaluate the effect of inhaled colistimethate sodium (study drug) compared with no study drug on the frequency of exacerbations (chest flare ups) and the number of exacerbation-free days over the 12 month treatment period.

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

  • Aged 18 or over with a diagnosis of non-cystic fibrosis bronchiectasis by CT scan.
  • At least two flare ups of your bronchiectasis requiring oral antibiotic treatment in the last 12 months (or one requiring intravenous antibiotic treatment in the last 12 months).
  • Sputum tested positive for P. Aeuruginosa in the last 12 months.

What's Involved

  • You will be required to attend up to 7 visits to Sir Charles Gairdner Hospital and complete 2 phone calls for up to approximately 14 months.
Register your interest in this Clinical Trial
  • This field is for validation purposes and should be left unchanged.
Current Clinical Trials